Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma

Lena Sehmisch, Stefan Huttenlocher, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aimed to identify clinical factors associated with survival and to develop a prognostic tool in patients receiving radiosurgery alone for very few cerebral metastases from melanoma. Ten characteristics of 69 patients treated with radiosurgery alone for 1-3 cerebral metastases from melanoma were retrospectively analyzed for survival. Serum lactate dehydrogenase levels before radiosurgery, Karnofsky performance score, maximum diameter of all irradiated cerebral lesions, and extracranial lesions were significantly associated with survival and included in the tool. Twelve-month survival rate (in %) divided by 10 was calculated for each of these four factors. The four scores were summed resulting in total scores ranging 9-22 points. Based on the 12-month survival rates, three groups were formed: less than 15 points (group I, n = 25); 15-20 points (group II, n = 34); and more than 20 points (group III, n = 10). Corresponding 12-month survival rates were 10 ± 6%, 51 ± 9% and 90 ± 9%, respectively (P < 0.001). In group I, death within 12 months following radiosurgery occurred mostly due to extracranial progression, whereas cerebral progression was the major cause of death in group II. In group III, only one of 10 patients died within 1 year. This new prognostic tool helps predict the survival time following radiosurgery of very few cerebral metastases from melanoma. An individual treatment approach should consider a patient's survival time and the most likely cause of death (cerebral or extracranial progression).

Original languageEnglish (US)
Pages (from-to)918-921
Number of pages4
JournalJournal of Dermatology
Volume41
Issue number10
DOIs
StatePublished - 2014

Fingerprint

Radiosurgery
Melanoma
Neoplasm Metastasis
Survival
Survival Rate
Cause of Death
L-Lactate Dehydrogenase
Serum

Keywords

  • Cerebral metastasis
  • Melanoma
  • Prognostic tool
  • Radiosurgery alone
  • Survival

ASJC Scopus subject areas

  • Dermatology

Cite this

Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma. / Sehmisch, Lena; Huttenlocher, Stefan; Schild, Steven E.; Rades, Dirk.

In: Journal of Dermatology, Vol. 41, No. 10, 2014, p. 918-921.

Research output: Contribution to journalArticle

Sehmisch, Lena ; Huttenlocher, Stefan ; Schild, Steven E. ; Rades, Dirk. / Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma. In: Journal of Dermatology. 2014 ; Vol. 41, No. 10. pp. 918-921.
@article{77df6c4fd16248f2b50922a44ba375bb,
title = "Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma",
abstract = "This study aimed to identify clinical factors associated with survival and to develop a prognostic tool in patients receiving radiosurgery alone for very few cerebral metastases from melanoma. Ten characteristics of 69 patients treated with radiosurgery alone for 1-3 cerebral metastases from melanoma were retrospectively analyzed for survival. Serum lactate dehydrogenase levels before radiosurgery, Karnofsky performance score, maximum diameter of all irradiated cerebral lesions, and extracranial lesions were significantly associated with survival and included in the tool. Twelve-month survival rate (in {\%}) divided by 10 was calculated for each of these four factors. The four scores were summed resulting in total scores ranging 9-22 points. Based on the 12-month survival rates, three groups were formed: less than 15 points (group I, n = 25); 15-20 points (group II, n = 34); and more than 20 points (group III, n = 10). Corresponding 12-month survival rates were 10 ± 6{\%}, 51 ± 9{\%} and 90 ± 9{\%}, respectively (P < 0.001). In group I, death within 12 months following radiosurgery occurred mostly due to extracranial progression, whereas cerebral progression was the major cause of death in group II. In group III, only one of 10 patients died within 1 year. This new prognostic tool helps predict the survival time following radiosurgery of very few cerebral metastases from melanoma. An individual treatment approach should consider a patient's survival time and the most likely cause of death (cerebral or extracranial progression).",
keywords = "Cerebral metastasis, Melanoma, Prognostic tool, Radiosurgery alone, Survival",
author = "Lena Sehmisch and Stefan Huttenlocher and Schild, {Steven E.} and Dirk Rades",
year = "2014",
doi = "10.1111/1346-8138.12599",
language = "English (US)",
volume = "41",
pages = "918--921",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Estimating survival of patients receiving radiosurgery alone for cerebral metastasis from melanoma

AU - Sehmisch, Lena

AU - Huttenlocher, Stefan

AU - Schild, Steven E.

AU - Rades, Dirk

PY - 2014

Y1 - 2014

N2 - This study aimed to identify clinical factors associated with survival and to develop a prognostic tool in patients receiving radiosurgery alone for very few cerebral metastases from melanoma. Ten characteristics of 69 patients treated with radiosurgery alone for 1-3 cerebral metastases from melanoma were retrospectively analyzed for survival. Serum lactate dehydrogenase levels before radiosurgery, Karnofsky performance score, maximum diameter of all irradiated cerebral lesions, and extracranial lesions were significantly associated with survival and included in the tool. Twelve-month survival rate (in %) divided by 10 was calculated for each of these four factors. The four scores were summed resulting in total scores ranging 9-22 points. Based on the 12-month survival rates, three groups were formed: less than 15 points (group I, n = 25); 15-20 points (group II, n = 34); and more than 20 points (group III, n = 10). Corresponding 12-month survival rates were 10 ± 6%, 51 ± 9% and 90 ± 9%, respectively (P < 0.001). In group I, death within 12 months following radiosurgery occurred mostly due to extracranial progression, whereas cerebral progression was the major cause of death in group II. In group III, only one of 10 patients died within 1 year. This new prognostic tool helps predict the survival time following radiosurgery of very few cerebral metastases from melanoma. An individual treatment approach should consider a patient's survival time and the most likely cause of death (cerebral or extracranial progression).

AB - This study aimed to identify clinical factors associated with survival and to develop a prognostic tool in patients receiving radiosurgery alone for very few cerebral metastases from melanoma. Ten characteristics of 69 patients treated with radiosurgery alone for 1-3 cerebral metastases from melanoma were retrospectively analyzed for survival. Serum lactate dehydrogenase levels before radiosurgery, Karnofsky performance score, maximum diameter of all irradiated cerebral lesions, and extracranial lesions were significantly associated with survival and included in the tool. Twelve-month survival rate (in %) divided by 10 was calculated for each of these four factors. The four scores were summed resulting in total scores ranging 9-22 points. Based on the 12-month survival rates, three groups were formed: less than 15 points (group I, n = 25); 15-20 points (group II, n = 34); and more than 20 points (group III, n = 10). Corresponding 12-month survival rates were 10 ± 6%, 51 ± 9% and 90 ± 9%, respectively (P < 0.001). In group I, death within 12 months following radiosurgery occurred mostly due to extracranial progression, whereas cerebral progression was the major cause of death in group II. In group III, only one of 10 patients died within 1 year. This new prognostic tool helps predict the survival time following radiosurgery of very few cerebral metastases from melanoma. An individual treatment approach should consider a patient's survival time and the most likely cause of death (cerebral or extracranial progression).

KW - Cerebral metastasis

KW - Melanoma

KW - Prognostic tool

KW - Radiosurgery alone

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84908464309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908464309&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.12599

DO - 10.1111/1346-8138.12599

M3 - Article

C2 - 25154301

AN - SCOPUS:84908464309

VL - 41

SP - 918

EP - 921

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 10

ER -